Abstract
Purpose of Review
To characterize and interpret recent studies of biomarkers of cardiorenal syndrome.
Recent Findings
Recent studies have questioned the mechanisms and significance of moderate worsening renal function (WRF) in patients with acute heart failure. In the setting of successful decongestion, WRF may not predict cardiorenal morbidity. Cardiac-specific biomarkers including cardiac troponins and natriuretic peptides are highly prognostic in acute and chronic HF patients with kidney impairment, and serial changes in these markers during hospitalization are also predictive of longer-term adverse outcomes. These markers also predict new HF in patients with established chronic kidney disease (CKD). The role of kidney tubular injury markers in acute HF remains controversial, with inconsistent associations with short- and long-term cardiorenal outcomes. Many cases of WRF in acute HF are not characterized by a clear pattern of renal tubular injury.
Summary
Cardiac-specific and renal-specific biomarkers may provide mechanistic and prognostic information in cardiorenal syndromes.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2009;31(6):703–11. https://doi.org/10.1093/eurheartj/ehp507.
Hanberg JS, Sury K, Wilson FP, Brisco MA, Ahmad T, ter Maaten JM, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol. 2016;67(19):2199–208. https://doi.org/10.1016/j.jacc.2016.02.058.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–96. https://doi.org/10.1016/j.jacc.2008.05.068.
• Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, et al. Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. Am Heart J. 2018;204:163–73. https://doi.org/10.1016/j.ahj.2018.07.019. Inovative analysis of trial data supporting the hypothesis that increaesed central venous pressures rather than forward cardiac flow determine worsening renal function, and that successful decongestion is a major prognostic marker rather than renal function.
•• Rangaswami J, Bhalla V, JEA B, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e78. https://doi.org/10.1161/cir.0000000000000664. Comprehensive overveiw of the cardiorenal syndromes, including classification, mechanisms, biomarkers, and therapeutics.
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–96. https://doi.org/10.1016/j.jacc.2005.11.084.
• Ronco C, Ronco F, McCullough PA. A call to action to develop integrated curricula in cardiorenal medicine. Blood Purif. 2017;44(4):251–9. https://doi.org/10.1159/000480318. Review and opinion on methods of defining expsoures and outcomes in cardiorenal syndromes.
deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem. 2007;53(8):1511–9. https://doi.org/10.1373/clinchem.2006.084533.
Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, et al. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC Heart Fail. 2015;3(10):751–61. https://doi.org/10.1016/j.jchf.2015.05.009.
Bansal N, Hyre Anderson A, Yang W, Christenson RH, deFilippi CR, Deo R, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the chronic renal insufficiency cohort (CRIC) study. J Am Soc Nephrol. 2015;26(4):946–56. https://doi.org/10.1681/asn.2014010108.
Schaub JA, Coca SG, Moledina DG, Gentry M, Testani JM, Parikh CR. Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and meta-analysis. JACC: Heart Failure. 2015;3(12):977–89. https://doi.org/10.1016/j.jchf.2015.07.014.
Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358(20):2117–26. https://doi.org/10.1056/NEJMoa0706824.
deFilippi C, Seliger SL, Kelley W, Duh SH, Hise M, Christenson RH, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem. 2012;58(9):1342–51. https://doi.org/10.1373/clinchem.2012.185322.
Parikh RH, Seliger SL. deFilippi CR. Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarction. Clin Biochem. 2015;48(4):247–53. https://doi.org/10.1016/j.clinbiochem.2015.01.004.
Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail. 2015;17(12):1262–70. https://doi.org/10.1002/ejhf.341.
•• Aimo A, Januzzi JL, Vergaro G, Ripoli A, Latini R, Masson S, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation. 2018;137(3):286–97. https://doi.org/10.1161/CIRCULATIONAHA.117.031560. Large individual meta-analysis demonstrating that hs-cTnI levels are strongly prognostic in CHF in patients with renal dysfunctin.
Maisel AS, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, et al. Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations: the AKINESIS study. J Am Coll Cardiol. 2016;68(13):1420–31. https://doi.org/10.1016/j.jacc.2016.06.055.
• Wettersten N, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, et al. Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. Eur J Heart Fail. 2020;22(2):251–63. https://doi.org/10.1002/ejhf.1642. Demonstrates that urinary NGAL - a widely studied urinary tubular injury biomarker - is not predictive of cardiorenal outcomes in acute heart failure.
Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Franci B, et al. Comparison of neutrophil gelatinase-associated Lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure. Am J Cardiol. 2015;116(1):104–11. https://doi.org/10.1016/j.amjcard.2015.03.043.
Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013;1(5):417–24. https://doi.org/10.1016/j.jchf.2013.05.007.
•• Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137(19):2016–28. https://doi.org/10.1161/circulationaha.117.030112. Secondary analysis of the ROSE-AHF trial showing that changes in urinary markers of tubular injury were not correlated with changes in renal function, suggesting that most cases of worsening renal function in AHF are not characterized by severe tubular injury.
• Brankovic M, Akkerhuis KM, van Boven N, Anroedh S, Constantinescu A, Caliskan K, et al. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney Int. 2018;93(4):952–60. https://doi.org/10.1016/j.kint.2017.09.013. Longutidinal observational study suggesting that long-term individual trajectories of tubular injury markers KIM-1 and NAG predict major adverse cardiovascular outcomes in chronic HF, independent of estimated glomerular filtration rate and other risk factors.
•• Lee AK, Katz R, Jotwani V, Garimella PS, Ambrosius WT, Cheung AK, et al. Distinct dimensions of kidney health and risk of cardiovascular fisease, heart failure, and mortality. Hypertension. 2019;74(4):872–9. https://doi.org/10.1161/HYPERTENSIONAHA.119.13339. Innovative analysis of multi-dimensional urinary and blood-based renal tubular and metabolic bone biomarkers in CKD patients in SPRINT, suggesting that markers of tubular reserve and metabolic metabolism predict new onset HF.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Stephen Seliger reports grants from Roche Diagnostics, Kadmon Corporation, Palladio Biosciences, Sanofi, and Reata and personal fees from Tricida Inc. In addition, Dr. Seliger has a patent “Methods for Assessing Differential Risk for Developing Heart Failure” (Patent No 10,509,044) issued.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Cardiac Biomarkers
Rights and permissions
About this article
Cite this article
Seliger, S. The Cardiorenal Syndrome: Mechanistic Insights and Prognostication with Soluble Biomarkers. Curr Cardiol Rep 22, 114 (2020). https://doi.org/10.1007/s11886-020-01360-8
Published:
DOI: https://doi.org/10.1007/s11886-020-01360-8